



**Figure S1** Preoperative total GLP-1 level stratified for different clinical conditions. (A) In diabetes, (B) in fibrosis, according to mild (f0-2) and severe fibrosis (f3-4) and (C) histologic phenotype of MASLD. MASLD, metabolic-dysfunction associated steatotic liver disease.

**Table S1** Binary logistic regression for PHLF (patient cohort 2)

	B	OR (95% CI)	P
BMI	0.075	1.09 (0.96–1.21)	0.207
MASLD	0.405	1.50 (0.41–5.50)	0.541
Diabetes	1.347	3.85 (1.06–13.91)	0.040
Preoperative chemotherapy	21.203	<0.001	0.998

PHLF, posthepatectomy liver failure; BMI, body mass index; MASLD, metabolic-dysfunction associated steatotic liver disease; B, the regression coefficient; OR, odds ratio; CI, confidence interval.

**Table S2** Spearman correlation of total GLP-1 and total GLP-2 with standard plasma lipid parameters

	Triglycerides	Total cholesterol	HDLc	LDLc	ApoA1	ApoB
<b>Total cohort</b>						
Total GLP-1	R=0.294 P=0.004	R=-0.176 P=0.093	R=-0.338 P=0.001	R=-0.164 P=0.122	R=-0.209 P=0.047	R=-0.063 P=0.555
Total GLP-2	R=0.025 P=0.814	R=-0.400 P=<0.001	R=-0.431 P≤0.001	R=-0.360 P≤0.001	R=-0.439 P≤0.001	R=-0.379 P≤0.001
<b>PHLF</b>						
Total GLP-1	R=0.381 P=0.050	R=0.069 P=0.734	R=-0.409 P=0.034	R=-0.077 P=0.702	R=-0.406 P=0.036	R=0.305 P=0.122
Total GLP-2	R=-0.098 P=0.628	R=-0.585 P=0.001	R=-0.534 P=0.004	R=-0.651 P<0.001	R=-0.418 P=0.030	R=-0.529 P=0.005

Non-parametrical correlation analysis of the total cohort and in patients who developed posthepatectomy liver failure (PHLF).